FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149482571> ?p ?o ?g. }

• W2149482571 endingPage "2139" @default.
• W2149482571 startingPage "2133" @default.
• W2149482571 abstract "The Apc(Min/+) mouse model is a clinically relevant model of early intestinal cancer. We used AZD2171, an oral, highly potent and selective vascular endothelial growth factor (VEGF) signaling inhibitor, to investigate the role of VEGF receptor-2 (VEGFR-2) signaling in adenoma development and growth in Apc(Min/+) mice. AZD2171 (5 mg/kg body wt/day) was administered once daily for 28 days to 6-week-old (early-intervention) or 10-week-old (late intervention) mice. In the early-intervention study, AZD2171 reduced the number of macroscopic polyps in the small bowel and colon. Macropolyp diameter was lower in the small bowel, but remained unchanged in the colon. In animals receiving AZD2171, microscopic evaluation of the small intestine showed a significant reduction in the number of larger lesions. In the late-intervention study, AZD2171 treatment reduced macropolyp diameter (but not number) in the small intestine. Microscopic analysis revealed that AZD2171 significantly reduced the number of larger micropolyps in the small bowel, with no large micropolyps present in the colon. AZD2171 treatment had no effect on microvessel density or localization of beta-catenin staining in adenomas or non-tumor intestinal tissue, but significantly reduced the number of cells expressing VEGFR-2 mRNA. In conclusion, the effects of AZD2171 in the small intestine of Apc(Min/+) mice are consistent with an antiangiogenic mechanism of action, limiting growth of adenomas to < or =1 mm. These data also suggest that an early step in adenoma development may depend on VEGFR-2 signaling. Together, these results indicate that VEGFR-2 signaling may play key roles in the development and progression of intestinal adenomas." @default.
• W2149482571 created "2016-06-24" @default.
• W2149482571 creator A5010402845 @default.
• W2149482571 creator A5012251107 @default.
• W2149482571 creator A5027141514 @default.
• W2149482571 creator A5043932592 @default.
• W2149482571 creator A5044215747 @default.
• W2149482571 creator A5055097014 @default.
• W2149482571 creator A5058765817 @default.
• W2149482571 creator A5065868509 @default.
• W2149482571 creator A5069898333 @default.
• W2149482571 creator A5079147077 @default.
• W2149482571 date "2006-08-02" @default.
• W2149482571 modified "2023-09-27" @default.
• W2149482571 title "Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer" @default.
• W2149482571 cites W1764097776 @default.
• W2149482571 cites W1894783768 @default.
• W2149482571 cites W1970053353 @default.
• W2149482571 cites W1983763042 @default.
• W2149482571 cites W1985804036 @default.
• W2149482571 cites W1990606472 @default.
• W2149482571 cites W2001258296 @default.
• W2149482571 cites W2005168722 @default.
• W2149482571 cites W2007311017 @default.
• W2149482571 cites W2020993185 @default.
• W2149482571 cites W2025708528 @default.
• W2149482571 cites W2034269086 @default.
• W2149482571 cites W2040387739 @default.
• W2149482571 cites W2041077743 @default.
• W2149482571 cites W2073212944 @default.
• W2149482571 cites W2080151878 @default.
• W2149482571 cites W2097373408 @default.
• W2149482571 cites W2102119680 @default.
• W2149482571 cites W2106253081 @default.
• W2149482571 cites W2106763792 @default.
• W2149482571 cites W2117444911 @default.
• W2149482571 cites W2123060447 @default.
• W2149482571 cites W2125052212 @default.
• W2149482571 cites W2136984317 @default.
• W2149482571 cites W2139631389 @default.
• W2149482571 cites W2147433377 @default.
• W2149482571 cites W2159789252 @default.
• W2149482571 cites W2166573361 @default.
• W2149482571 cites W2186242595 @default.
• W2149482571 cites W2239090104 @default.
• W2149482571 cites W2329360646 @default.
• W2149482571 cites W2398249700 @default.
• W2149482571 cites W2425892820 @default.
• W2149482571 cites W2804842145 @default.
• W2149482571 cites W1966109061 @default.
• W2149482571 doi "https://doi.org/10.1093/carcin/bgl113" @default.
• W2149482571 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16782971" @default.
• W2149482571 hasPublicationYear "2006" @default.
• W2149482571 type Work @default.
• W2149482571 sameAs 2149482571 @default.
• W2149482571 citedByCount "54" @default.
• W2149482571 countsByYear W21494825712012 @default.
• W2149482571 countsByYear W21494825712013 @default.
• W2149482571 countsByYear W21494825712014 @default.
• W2149482571 countsByYear W21494825712015 @default.
• W2149482571 countsByYear W21494825712016 @default.
• W2149482571 countsByYear W21494825712017 @default.
• W2149482571 countsByYear W21494825712019 @default.
• W2149482571 countsByYear W21494825712021 @default.
• W2149482571 countsByYear W21494825712022 @default.
• W2149482571 crossrefType "journal-article" @default.
• W2149482571 hasAuthorship W2149482571A5010402845 @default.
• W2149482571 hasAuthorship W2149482571A5012251107 @default.
• W2149482571 hasAuthorship W2149482571A5027141514 @default.
• W2149482571 hasAuthorship W2149482571A5043932592 @default.
• W2149482571 hasAuthorship W2149482571A5044215747 @default.
• W2149482571 hasAuthorship W2149482571A5055097014 @default.
• W2149482571 hasAuthorship W2149482571A5058765817 @default.
• W2149482571 hasAuthorship W2149482571A5065868509 @default.
• W2149482571 hasAuthorship W2149482571A5069898333 @default.
• W2149482571 hasAuthorship W2149482571A5079147077 @default.
• W2149482571 hasConcept C121608353 @default.
• W2149482571 hasConcept C126322002 @default.
• W2149482571 hasConcept C134018914 @default.
• W2149482571 hasConcept C167734588 @default.
• W2149482571 hasConcept C170493617 @default.
• W2149482571 hasConcept C2776280935 @default.
• W2149482571 hasConcept C2777025900 @default.
• W2149482571 hasConcept C2777428134 @default.
• W2149482571 hasConcept C2777882243 @default.
• W2149482571 hasConcept C2780394083 @default.
• W2149482571 hasConcept C502942594 @default.
• W2149482571 hasConcept C526805850 @default.
• W2149482571 hasConcept C71924100 @default.
• W2149482571 hasConcept C86803240 @default.
• W2149482571 hasConceptScore W2149482571C121608353 @default.
• W2149482571 hasConceptScore W2149482571C126322002 @default.
• W2149482571 hasConceptScore W2149482571C134018914 @default.
• W2149482571 hasConceptScore W2149482571C167734588 @default.
• W2149482571 hasConceptScore W2149482571C170493617 @default.
• W2149482571 hasConceptScore W2149482571C2776280935 @default.
• W2149482571 hasConceptScore W2149482571C2777025900 @default.
• W2149482571 hasConceptScore W2149482571C2777428134 @default.

• next